Somewhat Positive News Coverage Somewhat Unlikely to Impact Columbia Laboratories (JNP) Share Price

Media stories about Columbia Laboratories (NASDAQ:JNP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Columbia Laboratories earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.314104879015 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of JNP traded up $0.10 during mid-day trading on Monday, hitting $10.50. The stock had a trading volume of 30,417 shares, compared to its average volume of 98,709. The firm has a market cap of $114.14, a PE ratio of -68.60 and a beta of 0.46. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.20 and a quick ratio of 1.81. Columbia Laboratories has a 52 week low of $3.65 and a 52 week high of $13.25.

How to Become a New Pot Stock Millionaire

Columbia Laboratories (NASDAQ:JNP) last issued its earnings results on Thursday, March 8th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.22. The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $16.00 million. Columbia Laboratories had a negative return on equity of 3.91% and a negative net margin of 4.12%. sell-side analysts anticipate that Columbia Laboratories will post 3.5 earnings per share for the current fiscal year.

Several brokerages have issued reports on JNP. ValuEngine upgraded Columbia Laboratories from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Roth Capital began coverage on Columbia Laboratories in a research note on Tuesday, January 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Finally, TheStreet upgraded Columbia Laboratories from a “c+” rating to a “b-” rating in a research note on Monday, March 12th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Columbia Laboratories has a consensus rating of “Buy” and a consensus price target of $29.00.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3343472/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-columbia-laboratories-jnp-share-price.html.

About Columbia Laboratories

Juniper Pharmaceuticals, Inc, a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology.

Insider Buying and Selling by Quarter for Columbia Laboratories (NASDAQ:JNP)

Receive News & Ratings for Columbia Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Columbia Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head to Head Comparison: Commercial Metals  & Titan International
Head to Head Comparison: Commercial Metals & Titan International
Match Group  Expected to Post Quarterly Sales of $386.66 Million
Match Group Expected to Post Quarterly Sales of $386.66 Million
Financial Analysis: Sharps Compliance  & Clean Harbors
Financial Analysis: Sharps Compliance & Clean Harbors
Flaherty & Crumrine  Receives Media Sentiment Rating of 0.00
Flaherty & Crumrine Receives Media Sentiment Rating of 0.00
Head-To-Head Analysis: Suez Environnement  & Profire Energy
Head-To-Head Analysis: Suez Environnement & Profire Energy
EmberCoin  Price Reaches $0.0000
EmberCoin Price Reaches $0.0000


Leave a Reply

© 2006-2018 Ticker Report. Google+.